OBJECTIVES: HIV infection is associated with dyslipidaemia and increased risk of cardiovascular disease. The effects of HIV infection and antiretroviral treatment on surrogate markers of atherosclerosis, and lipoprotein metabolism were evaluated in a 12 month prospective study. METHODS AND RESULTS: Treatment-naive HIV patients were recruited into one of three groups: untreated HIV infection not likely to require initiation of antiretroviral therapy (ART) for at least 12 months; initiating treatment with non nucleoside reverse transcriptase inhibitor-containing ART regimen and initiating treatment with protease inhibitor-containing ART regimen. The patients underwent assessment of carotid intima-media thickness (cIMT), pulse wave velocity (PWV), brachial flow-mediated dilation (FMD) and variables of plasma lipoprotein metabolism at baseline and 12 months. The findings were compared with published values for age and sex matched HIV-negative healthy subjects in a cross-sectional fashion. cIMT and FMD were lower while PWV was higher in HIV-patients compared with HIV-negative individuals; none of the markers changed significantly during 12 months follow up. HIV patients had hypoalphalipoproteinemia and elevated plasma levels of lecithin:cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein. The only significant changes in lipid-related variables were elevation of total cholesterol and triglycerides in patients treated with PI-containing regimen and elevation of plasma LCAT levels in patients treated with NNRTI-containing regimen. The ability of whole and apoB-depleted plasma to effect cholesterol efflux was not impaired in all three groups. CONCLUSIONS: This study did not find evidence for rapid progression of subclinical atherosclerosis and deterioration of dyslipidaemia in HIV patients within 1 year.
OBJECTIVES:HIV infection is associated with dyslipidaemia and increased risk of cardiovascular disease. The effects of HIV infection and antiretroviral treatment on surrogate markers of atherosclerosis, and lipoprotein metabolism were evaluated in a 12 month prospective study. METHODS AND RESULTS: Treatment-naive HIV patients were recruited into one of three groups: untreated HIV infection not likely to require initiation of antiretroviral therapy (ART) for at least 12 months; initiating treatment with non nucleoside reverse transcriptase inhibitor-containing ART regimen and initiating treatment with protease inhibitor-containing ART regimen. The patients underwent assessment of carotid intima-media thickness (cIMT), pulse wave velocity (PWV), brachial flow-mediated dilation (FMD) and variables of plasma lipoprotein metabolism at baseline and 12 months. The findings were compared with published values for age and sex matched HIV-negative healthy subjects in a cross-sectional fashion. cIMT and FMD were lower while PWV was higher in HIV-patients compared with HIV-negative individuals; none of the markers changed significantly during 12 months follow up. HIV patients had hypoalphalipoproteinemia and elevated plasma levels of lecithin:cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein. The only significant changes in lipid-related variables were elevation of total cholesterol and triglycerides in patients treated with PI-containing regimen and elevation of plasma LCAT levels in patients treated with NNRTI-containing regimen. The ability of whole and apoB-depleted plasma to effect cholesterol efflux was not impaired in all three groups. CONCLUSIONS: This study did not find evidence for rapid progression of subclinical atherosclerosis and deterioration of dyslipidaemia in HIV patients within 1 year.
Authors: Isabella Sudano; Lukas E Spieker; Georg Noll; Roberto Corti; Rainer Weber; Thomas F Lüscher Journal: Am Heart J Date: 2006-06 Impact factor: 4.749
Authors: Judith S Currier; Michelle A Kendall; Robert Zackin; W Keith Henry; Beverly Alston-Smith; Francesca J Torriani; Jeff Schouten; Keith Mickelberg; Yanjie Li; Howard N Hodis Journal: AIDS Date: 2005-06-10 Impact factor: 4.177
Authors: P Mercié; R Thiébaut; V Aurillac-Lavignolle; J L Pellegrin; M C Yvorra-Vives; C Cipriano; D Neau; P Morlat; J M Ragnaud; M Dupon; F Bonnet; S Lawson-Ayayi; D Malvy; R Roudaut; F Dabis Journal: HIV Med Date: 2005-11 Impact factor: 3.180
Authors: Jeroen P H van Wijk; Eelco J P de Koning; Manuel Castro Cabezas; Jorge Joven; Jos op't Roodt; Ton J Rabelink; Andy M Hoepelman Journal: J Am Coll Cardiol Date: 2006-02-23 Impact factor: 24.094
Authors: Judith S Currier; Michelle A Kendall; W Keith Henry; Beverly Alston-Smith; Francesca J Torriani; Pablo Tebas; Yanjie Li; Howard N Hodis Journal: AIDS Date: 2007-05-31 Impact factor: 4.177
Authors: Zahedi Mujawar; Honor Rose; Matthew P Morrow; Tatiana Pushkarsky; Larisa Dubrovsky; Nigora Mukhamedova; Ying Fu; Anthony Dart; Jan M Orenstein; Yuri V Bobryshev; Michael Bukrinsky; Dmitri Sviridov Journal: PLoS Biol Date: 2006-10 Impact factor: 8.029
Authors: Marc O Siegel; Alison G Borkowska; Larisa Dubrovsky; Mary Roth; Ruth Welti; Afsoon D Roberts; David M Parenti; Gary L Simon; Dmitri Sviridov; Samuel Simmens; Michael Bukrinsky; Michael L Fitzgerald Journal: Atherosclerosis Date: 2015-08-29 Impact factor: 5.162
Authors: Hann Low; Lesley Cheng; Maria-Silvana Di Yacovo; Melissa J Churchill; Peter Meikle; Michael Bukrinsky; Andrew F Hill; Dmitri Sviridov Journal: Atherosclerosis Date: 2015-10-30 Impact factor: 5.162
Authors: Titus Msoka; Josephine Rogath; Gary Van Guilder; Gibson Kapanda; Yvo Smulders; Marceline Tutu van Furth; John Bartlett; Michiel van Agtmael Journal: HIV AIDS (Auckl) Date: 2021-06-03